Among existing pharmaceuticals, -fluoxetine -desipramine -imipramine -topiramatehave been suggested to be effectivein the treatment of binge style eating,while -phentermine -diethylpropion -orlistatare often provided for obesity.Newly approved by FDA are -locaserin hydrochloride (Belviq) -phentermine + topiramate extended release (Qsymia)for treatment of chronic weight management and -alogliptin (Nesina) for treatment of type 2 diabetesReferences

1. Powell AG, Apovian CM, Aronne LJ. New drug targets for the treatment of obesity. Clin Pharmacol Ther. 2011; 90(1), 40-51.

1. Korner J, Aronne LJ. Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab. 2004; 89(6), 2616-2621.

1. Claudine AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007; 68(9), 1324-1332.